ReviewPhytotherapy research : PTR2025
Phytoestrogen Signal Pathways and Estrogen Signaling in Ovarian Cancer: A Narrative Review.
Review in Phytotherapy research : PTR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Biological activities and therapeutic potential of soy isoflavones: a focus on anticancer activity.Molecular biology reports · 2026Review
- GPER agonist G1 suppresses neuronal apoptosis mediated by endoplasmic reticulum stress after exertional heat stroke injury.Scientific reports · 2026Article
- Impact of plant-based interventions on gynecological cancers: a narrative review of mechanistic interplays and clinical evidence.Frontiers in molecular medicine · 2026Review
- Improvement of Menopausal Symptoms byFood science & nutrition · 2025Article
- The role of pyroptosis in ovarian cancer.Discover oncology · 2025Review
- Phytoestrogen Signal Pathways and Estrogen Signaling in Ovarian Cancer: A Narrative Review.Phytotherapy research : PTR · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) is the second most common gynecological cancer and the leading cause of death from gynecological malignancies. Ovarian cancer mortality rate ranks fifth among cancer-related deaths in Western societies. Hence, novel preventive and therapeutic ways are still in great demand to reduce the incidence and mortality rate of ovarian cancer. Phytoestrogens, referred to as dietary estrogens, provide benefits to all mammals, including humans. Research indicates that phytoestrogens may be possible hormonal treatment options for ovarian cancer patients. They are non-steroidal plant compounds that undergo metabolism to produce compounds structurally and functionally related to ovarian and placental estrogens. Some studies suggest that estrogen receptors (ER-α and ER-β) and G protein-coupled estrogen receptor (GPER) are potential targets for ovarian cancer prevention and treatment. Current studies indicate multiple signal pathways of phytoestrogens in the management of ovarian cancer. Even so, literature suggests that the signaling mechanisms in ovarian cancer and the signaling mechanisms of phytoestrogens are still not exactly understood. With this, phytoestrogens may act on multiple signaling pathways such as ER (endoplasmic reticulum)-dependent signaling, GnRH receptor, FSH or LH receptors and hormones, and GFR, which help to regulate the expression of AKT, RAS, RAF, Caspase-3, NF-kB, and Bcl-2. In summary, this narrative review discusses the possible targets of phytoestrogens in ovarian cancer and sheds a light on improving novel phytoestrogens-based dietary supplements against ovarian cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.